☆ 4.5 Editorial Material

JAK inhibitors and VTE risk: how concerned should we be?

NATURE REVIEWS RHEUMATOLOGY (2021)

Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis

Mark Yates et al.

Summary: A meta-analysis of RCT data on JAK inhibitors in IMID patients found a low risk of VTE, not supporting current warnings. These findings will help in the continued development of clinical guidelines for the use of JAK inhibitors in IMIDs.

ARTHRITIS & RHEUMATOLOGY (2021)

添加到收藏夹

Article Rheumatology

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

Stanley B. Cohen et al.

Summary: In the phase III clinical trials for RA, patients treated with upadacitinib at 15 mg and 30 mg doses had higher rates of upper respiratory tract infection, nasopharyngitis, and urinary tract infection compared to those on methotrexate and adalimumab. Serious infection rates were similar between upadacitinib 15 mg and adalimumab, but higher than methotrexate, while rates of herpes zoster and CPK elevations were higher with both upadacitinib doses. Rates of deaths, malignancies, MACEs, and VTEs were similar across all treatment groups.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Rheumatology